Indication: Breast Cancer

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE)

Metastatic Triple Negative

Sub-indication: Metastatic Triple negative breast cancer 2nd line

Line of Therapy: Metastatic triple negative breast cancer 2nd line (1st line needs to be anthracycline and/or taxane)

Drug Study

Principal Investigator: Laila Agrawal, M.D.
Norton Cancer Institute

Sponsor: AstraZeneca

Learn more at ClinicalTrials.gov

Email for more information: Breast-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.